Business Strategy

Combos, New MOAs, And Oral Formulations Of Injectables: Lilly’s Immunology Strategy

 
• By 

In a competitive immunology landscape, Eli Lilly is looking for novel agents, oral formulations of injectables, and combination therapies that can optimize response and expand the patient pool.

AI Starts To Make Its Mark In Pharma Marketing

 

The early adoption of artificial intelligence/machine learning has centered around drug discovery, but the technologies are being applied to other fields, including pharma marketing.

Big Pharma GCCs In India: From Back-Office Ops To Innovation Catalysts

 

India is seeing a flurry of activity with big pharma either establishing or expanding their global capability centers in the country. Can these hubs reshape the contours of industry’s operating model across a range of functions and perhaps spawn a pipeline of new leaders along the way?

Deal Volume Up, Value Down During The First Half

 
• By 

Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.


Boehringer R&D Exec: ‘People Are Longing For Connection’

 
• By 

In her role as Boehringer's senior vice president and global head of Development Sciences, Xiaorong He emphasizes patient-centric innovation and sustainability. She is committed to incorporating patient insights into product development and advancing eco-friendly practices within the company's R&D pipeline.  

Four Reasons Oncology Needs Digital Health Innovation

 

Together, Merck’s heads of oncology and head of digital health outline their cross-functional strategy to enhance care for cancer patients through digital tools.

Titans Of Pharma: J&J Back On Top For CEO Remuneration

 

J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.  

Parexel Execs On Obesity, AI And Data Trends

 
• By 

Parexel’s chief strategy officer Kushal Gohil, clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India.    


Why CAR T Therapies Are Hard To Scale, And How Challenges Can Be Solved

 

Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized the treatment of blood cancer, but scalability remains a major challenge. Experts explain how technologies such as chip-based miniaturized models and automation could be part of the solution.  

Regeneron Aiming To Be A Cell And Gene Medicine ‘Powerhouse’

 

Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline. 

How Debiopharm’s Licensing Model Bridges The Biotech And Pharma Gap

 

Sandra von Meier, head of business development and licensing at Debiopharm explains how the company’s distinctive licensing business model is helping bring new drugs to market.  

ASCO Roundup: Looking For The Future Of Cancer Research

 

As the American Society of Clinical Oncology annual meeting drew to a close, industry execs discussed staying competitive, adjusting to policy changes and how artificial intelligence is advancing cancer R&D.


How Cellino’s Cassette Technology Will Impact Regenerative Medicine

 
• By 

Co-founder and CEO of Cellino Biotech, Nabiha Saklayen, discusses the company’s innovative platform which uses automated technologies to overcome challenges in the development of regenerative medicine.

Development Versus Dealmaking: How To Obtain A Blockbuster

 
• By 

Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.  

The Truly Transformational Potential Of AI Relies On The Data

 
• By 

Executives from several AI-focused biotechs emphasize that generating a truly innovative medicine, as opposed to a me-too drug, depends not just on the quantity, but on the quality of data used by the algorithm.    

Rezo’s Platform Could ‘Fundamentally Shift’ Drug Discovery

 

Rezo’s chief technology officer Sourav Bandyopadhyay discusses the company's focus on leveraging AI and machine learning to accelerate drug discovery and its potential for partnerships with big pharma.  


The R&D Technology Stack: How Pharma Can Gain A Competitive Edge With AI, Data And Tech

 
• By 

The use of Artificial intelligence, data analytics and digital technologies hold the potential to transform pharmaceutical R&D and massively improve productivity. However, to achieve game-changing impact, the right technology infrastructure is required.  

Entering Estonia: To Build Bigger Castles, You Need A Better Sandbox

 

Estonia is hoping to  create a brighter future by attracting leading startups to its borders, a process that will bring tax revenues, jobs and infrastructure.

Why Are Clinical Development Success Rates Falling?

 
• By 

A recent analysis from Biomedtracker of clinical trial phase transitions between 2014 and 2023 suggests biopharma development success rates are falling. This poses several questions: what are the underlying reasons dragging success rates down and what does this mean for R&D productivity and the return on investment on pipeline spend?

Agnė Vaitkevičienė: The Versatile CEO Driving Memel Biotech

 

Rising star Agnė Vaitkevičienė is juggling roles as the CEO of an emerging Lithuanian biotech, with work for a partner company, the national biotech trade association and much more.